SCHEMBL14440751

SCHEMBL14440751

CCN(C(=O)Nc1cc(C(F)(F)F)ccc1C(=O)N1CCS(=O)(=O)CC1)c1ccc(Oc2ccncc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.43
MMP9 P14780 4/20 0.43
SCN9A Q15858 5/20 0.41
RPS6KB1 P23443 1/20 0.39
SCN7A Q01118 1/20 0.38
KCNH2 Q12809 1/20 0.38
KDR P35968 2/20 0.38
BRAF P15056 1/20 0.38
MAPK14 Q16539 1/20 0.38
TNNI3K Q59H18 1/20 0.38
ALOX5AP P20292 2/20 0.37
FEN1 P39748 2/20 0.37
SRC P12931 1/20 0.37
EPHX2 P34913 1/20 0.36
RAF1 P04049 1/20 0.36
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
FAAH O00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4758902 0.83 KDR (0.55) RPS6KB1KDRBRAFMAPK14TNNI3K
SCHEMBL4710239 0.73 RAF1 (0.66) RPS6KB1KDRBRAFMAPK14TNNI3K
SCHEMBL14440750 0.72 ALOX5AP (0.46) SCN9AMAPK14ALOX5APFEN1EPHX2
SCHEMBL14440754 0.72 RAF1 (0.55) RPS6KB1KCNH2KDRBRAFMAPK14
SCHEMBL14440755 0.71 RAF1 (0.57) RPS6KB1KCNH2KDRBRAFMAPK14
SCHEMBL13625523 0.71 RPS6KB1 (0.54) RPS6KB1MAPK14
SCHEMBL4760173 0.69 BRAF (0.57) RPS6KB1KDRBRAFMAPK14TNNI3K
SCHEMBL13625520 0.65 MAPK14 (0.57) RPS6KB1MAPK14
SCHEMBL14440752 0.65 ALOX5AP (0.55) SCN9AALOX5APFEN1EPHX2
SCHEMBL13315102 0.65 MAPK14 (0.68) RPS6KB1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185098-A1 Inhibitors of protein kinases LOCUS PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185098-A1 Inhibitors of protein kinases MAP3K20, MAP3K1, MAP3K19 MMP2 1865/4885MMP9 2828/4885SCN9A 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.